Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Amyloid-β, a hallmark of Alzheimer's disease, begins accumulating up to two decades before the onset of dementia, and can be detected in vivo applying amyloid-β positron emission tomography tracers such as carbon-11-labelled Pittsburgh compound-B. A variety of thresholds have been applied in the literature to define Pittsburgh compound-B positron emission tomography positivity, but the ability of these thresholds to detect early amyloid-β deposition is unknown, and validation studies comparing Pittsburgh compound-B thresholds to post-mortem amyloid burden are lacking. In this study we first derived thresholds for amyloid positron emission tomography positivity using Pittsburgh compound-B positron emission tomography in 154 cognitively normal older adults with four complementary approaches: (i) reference values from a young control group aged between 20 and 30 years; (ii) a Gaussian mixture model that assigned each subject a probability of being amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B index uptake; (iii) a k-means cluster approach that clustered subjects into amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B uptake in different brain regions (features); and (iv) an iterative voxel-based analysis that further explored the spatial pattern of early amyloid-β positron emission tomography signal. Next, we tested the sensitivity and specificity of the derived thresholds in 50 individuals who underwent Pittsburgh compound-B positron emission tomography during life and brain autopsy (mean time positron emission tomography to autopsy 3.1 ± 1.8 years). Amyloid at autopsy was classified using Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria, unadjusted for age. The analytic approaches yielded low thresholds (standard uptake value ratiolow = 1.21, distribution volume ratiolow = 1.08) that represent the earliest detectable Pittsburgh compound-B signal, as well as high thresholds (standard uptake value ratiohigh = 1.40, distribution volume ratiohigh = 1.20) that are more conservative in defining Pittsburgh compound-B positron emission tomography positivity. In voxel-wise contrasts, elevated Pittsburgh compound-B retention was first noted in the medial frontal cortex, then the precuneus, lateral frontal and parietal lobes, and finally the lateral temporal lobe. When compared to post-mortem amyloid burden, low proposed thresholds were more sensitive than high thresholds (sensitivities: distribution volume ratiolow 81.0%, standard uptake value ratiolow 83.3%; distribution volume ratiohigh 61.9%, standard uptake value ratiohigh 62.5%) for CERAD moderate-to-frequent neuritic plaques, with similar specificity (distribution volume ratiolow 95.8%; standard uptake value ratiolow, distribution volume ratiohigh and standard uptake value ratiohigh 100.0%). A receiver operator characteristic analysis identified optimal distribution volume ratio (1.06) and standard uptake value ratio (1.20) thresholds that were nearly identical to the a priori distribution volume ratiolow and standard uptake value ratiolow. In summary, we found that frequently applied thresholds for Pittsburgh compound-B positivity (typically at or above distribution volume ratiohigh and standard uptake value ratiohigh) are overly stringent in defining amyloid positivity. Lower thresholds in this study resulted in higher sensitivity while not compromising specificity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806716PMC
http://dx.doi.org/10.1093/brain/awv112DOI Listing

Publication Analysis

Top Keywords

pittsburgh compound-b
48
positron emission
36
emission tomography
36
standard uptake
36
distribution volume
36
compound-b positron
20
uptake ratiolow
16
volume ratiolow
16
uptake ratiohigh
16
volume ratiohigh
16

Similar Publications

BackgroundThe relationship between blood pressure (BP) trajectories across early (∼40 years) into mid-life (∼55 years) and preclinical dementia has not previously been well studied using positron emission tomography (PET) imaging outcomes.ObjectiveTo examine the association between BP trajectories across early mid-life into mid mid-life and amyloid- and tau-PET burden in adults without clinical dementia.MethodsThis prospective cohort study included dementia-free Framingham Heart Study 3 generation participants with data on remote BP (2002-2005) and recent BP (2016-2019) who participated in C-Pittsburgh Compound-B (PiB)-PET and/or F-Flortaucipir (FTP)-PET scans between 2016 to 2022.

View Article and Find Full Text PDF

Introduction: Amyloid positron emission tomography (PET) allows in vivo measurement of amyloid plaque deposition; however, different tracers lead to different results. We test the hypothesis that the variability in amyloid measurements is related to white matter retention, and accounting for this variability can improve agreements.

Methods: Data from the Centiloid project was downloaded and processed for four F18 tracer-to-Pittsburgh Compound B (PiB) pairs to obtain mean cortical standardized uptake value ratio (MCSUVR).

View Article and Find Full Text PDF

[Longitudinal follow-up in patients with dementia with Lewy bodies: clinical and multimodal imaging characteristics].

Zhonghua Yi Xue Za Zhi

August 2025

Department of Neurology, the Second Medical Centre and National Clinical Research Center for Geriatric Disease, Chinese PLA General Hospital, Beijing 100853, China.

To characterize the clinical and imaging features of Dementia with Lewy Bodies (DLB) through long-term follow-up. This study analyzed clinical and multimodal imaging data, including magnetic resonance imaging (MRI), dopamine transporter (DAT), C Pittsburgh compound B (C-PIB), and F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET), from 11 probable DLB patients at the first and second medical center of PLA General Hospital from March 2012 to February 2025. Patients were longitudinally assessed for the following parameters: time from disease onset to bedridden status, time from onset to death, annual cognitive decline rate (measured by mini-mental state examination, MMSE), extent of cerebral atrophy, regions of hypometabolism, and areas of reduced DAT availability.

View Article and Find Full Text PDF

Introduction: We investigated whether age of patients with Alzheimer's disease (AD) at first visit to a memory clinic predicts biomarker findings along the amyloid beta deposition, pathologic tau, and neurodegeneration (ATN) scheme and moderates the association between ATN biomarkers and cognition.

Methods: We evaluated [C]Pittsburgh compound B positron emission tomography (PET), florzolotau (F) PET, [F]fluorodeoxyglucose PET, T1-weighted magnetic resonance imaging, and cognitive assessments ( = 190/63/252/687/2198) of a total of 2355 AD patients. We assessed direct and moderating effects of age.

View Article and Find Full Text PDF

Introduction: Adults with Down syndrome (DS) accumulate amyloid beta (Aβ) plaques faster and earlier on average than neurotypical adults with sporadic Alzheimer's disease (AD). White matter (WM) microstructure characterized with diffusion tensor imaging (DTI) can indicate underlying architectural changes in longitudinal studies, suggestive of neurodegeneration. This study investigated relationships between DTI and Aβ in DS along the AD continuum.

View Article and Find Full Text PDF